[go: up one dir, main page]

DE69525643T2 - Sulfur-substituierte azetdinone als hypocholesterolmischmittel - Google Patents

Sulfur-substituierte azetdinone als hypocholesterolmischmittel

Info

Publication number
DE69525643T2
DE69525643T2 DE69525643T DE69525643T DE69525643T2 DE 69525643 T2 DE69525643 T2 DE 69525643T2 DE 69525643 T DE69525643 T DE 69525643T DE 69525643 T DE69525643 T DE 69525643T DE 69525643 T2 DE69525643 T2 DE 69525643T2
Authority
DE
Germany
Prior art keywords
fluorophenyl
azetidinone
formula
aryl
coor6
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69525643T
Other languages
German (de)
English (en)
Other versions
DE69525643D1 (de
Inventor
A. Burnett
Sundeep Dugar
A. Mckittrick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/342,197 external-priority patent/US5624920A/en
Application filed by Schering Corp filed Critical Schering Corp
Publication of DE69525643D1 publication Critical patent/DE69525643D1/de
Application granted granted Critical
Publication of DE69525643T2 publication Critical patent/DE69525643T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
DE69525643T 1994-11-18 1995-11-15 Sulfur-substituierte azetdinone als hypocholesterolmischmittel Expired - Lifetime DE69525643T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/342,197 US5624920A (en) 1994-11-18 1994-11-18 Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US08/463,619 US5633246A (en) 1994-11-18 1995-06-05 Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
PCT/US1995/014134 WO1996016037A1 (en) 1994-11-18 1995-11-15 Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents

Publications (2)

Publication Number Publication Date
DE69525643D1 DE69525643D1 (de) 2002-04-04
DE69525643T2 true DE69525643T2 (de) 2002-09-26

Family

ID=26992866

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69525643T Expired - Lifetime DE69525643T2 (de) 1994-11-18 1995-11-15 Sulfur-substituierte azetdinone als hypocholesterolmischmittel

Country Status (24)

Country Link
US (2) US5633246A (pt)
EP (1) EP0792264B1 (pt)
JP (1) JP2908031B2 (pt)
KR (1) KR100235806B1 (pt)
CN (1) CN1083833C (pt)
AT (1) ATE213726T1 (pt)
AU (1) AU698750B2 (pt)
BR (1) BR9509669A (pt)
CA (1) CA2205202C (pt)
CZ (1) CZ289033B6 (pt)
DE (1) DE69525643T2 (pt)
DK (1) DK0792264T3 (pt)
ES (1) ES2169162T3 (pt)
FI (1) FI116220B (pt)
HU (1) HU227672B1 (pt)
MX (1) MX9703577A (pt)
NO (1) NO308468B1 (pt)
NZ (1) NZ296720A (pt)
PL (1) PL184310B1 (pt)
PT (1) PT792264E (pt)
RU (1) RU2159243C2 (pt)
SK (1) SK283860B6 (pt)
UA (1) UA54381C2 (pt)
WO (1) WO1996016037A1 (pt)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
CA2235943C (en) 1995-10-31 2002-10-01 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
CA2336003A1 (en) * 1998-06-25 1999-12-29 Zhongmin Xu Amidino and guanidino azetidinone tryptase inhibitors
US6297268B1 (en) 1999-11-30 2001-10-02 Schering Corporation Imidazoles as cholesterol lowering agents
US6584357B1 (en) * 2000-10-17 2003-06-24 Sony Corporation Method and system for forming an acoustic signal from neural timing difference data
IL155771A0 (en) * 2000-12-20 2003-12-23 Schering Corp Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
EP1510521A1 (en) * 2000-12-20 2005-03-02 Schering Corporation Sugar-substituted 2-Azetidinones useful as hypocholesterolemic agents
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
ME00145B (me) * 2001-01-26 2010-10-10 Merck Sharp & Dohme Upotreba supstituisanih jedinjenja azetidinona za lečenje sitosterolemije
EP1911462A3 (en) 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US20060287254A1 (en) * 2001-01-26 2006-12-21 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
WO2002079174A2 (en) 2001-03-28 2002-10-10 Schering Corporation Enantioselective synthesis of azetidinone intermediate compounds
EP1859796A3 (en) * 2001-09-21 2008-07-02 Schering Corporation Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
ES2272776T3 (es) 2001-09-21 2007-05-01 Schering Corporation Tratamiento de xantomas con derivados de azetidinona como inhibidores de la absorcion de esterol.
US20030204096A1 (en) * 2002-03-25 2003-10-30 Schering Corporation Enantioselective synthesis of azetidinone intermediate compounds
GB0215579D0 (en) * 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
US7135556B2 (en) * 2002-07-19 2006-11-14 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
WO2004043457A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
DE602004016123D1 (de) 2003-03-07 2008-10-09 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
DE602004018617D1 (de) 2003-03-07 2009-02-05 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
US7192944B2 (en) 2003-03-07 2007-03-20 Schering Corp. Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
DE10314610A1 (de) * 2003-04-01 2004-11-04 Aventis Pharma Deutschland Gmbh Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
WO2005021039A1 (en) * 2003-08-29 2005-03-10 Cotherix, Inc. Combination of cicletanine and an oral antidiabetic and/or blood lipid-lowering agent for treating diabetes and metabolic syndrome
EP1522541A1 (en) * 2003-10-07 2005-04-13 Lipideon Biotechnology AG Novel hypocholesterolemic compounds
EP1918000A2 (en) 2003-11-05 2008-05-07 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
WO2005062824A2 (en) * 2003-12-23 2005-07-14 Merck & Co., Inc. Anti-hypercholesterolemic compounds
GB0329778D0 (en) * 2003-12-23 2004-01-28 Astrazeneca Ab Chemical compounds
RU2380360C2 (ru) * 2003-12-23 2010-01-27 Астразенека Аб Дифенилазетидиноновые производные, обладающие активностью, ингибирующей всасывание холестерина
BRPI0418004A (pt) * 2003-12-23 2007-04-17 Astrazeneca Ab composto ou um sal, solvato, solvato de um tal sal ou uma pró-droga deste farmaceuticamente aceitáveis, métodos para tratar ou prevenir condições hiperlipidêmicas, aterosclerose, mal de alzheimer, e tumores associados com colesterol, formulação farmacêutica, combinação, e, processo para preparar um composto ou um sal, solvato, solvato de um tal sal ou uma pró-droga deste farmaceuticamente aceitáveis
US7901893B2 (en) * 2004-01-16 2011-03-08 Merck Sharp & Dohme Corp. NPC1L1 (NPC3) and methods of identifying ligands thereof
CA2581596A1 (en) * 2004-09-29 2006-04-13 Schering Corporation Combinations of substituted azetidonones and cb1 antagonists
CN101115726A (zh) 2004-12-03 2008-01-30 先灵公司 作为cb1拮抗剂的取代哌嗪
UY29607A1 (es) * 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
US7635705B2 (en) * 2005-06-20 2009-12-22 Schering Corporation Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists
AR057383A1 (es) * 2005-06-22 2007-12-05 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
AR054482A1 (es) * 2005-06-22 2007-06-27 Astrazeneca Ab Derivados de azetidinona para el tratamiento de hiperlipidemias
MY148538A (en) * 2005-06-22 2013-04-30 Astrazeneca Ab Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
AR056866A1 (es) * 2005-06-22 2007-10-31 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, una formulacion farmaceutica y un proceso de preparacion del compuesto
SA06270191B1 (ar) * 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
AR057380A1 (es) * 2005-06-22 2007-11-28 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos
US20070161578A1 (en) * 2005-12-21 2007-07-12 Hwa Joyce J Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or H3 receptor antagonist/inverse agonist
PE20071320A1 (es) 2006-01-18 2007-12-29 Schering Corp Moduladores de receptores cannabinoides
EP1986489A2 (en) * 2006-02-24 2008-11-05 Schering Corporation Npc1l1 orthologues
CA2644905A1 (en) * 2006-03-06 2007-09-13 Teva Pharmaceutical Industries Ltd. Ezetimibe compositions
TW200811098A (en) 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
JP2010502702A (ja) * 2006-09-05 2010-01-28 シェーリング コーポレイション 脂質管理およびアテローム性動脈硬化症および脂肪肝の治療治療において使用される医薬組成物
WO2008033468A2 (en) 2006-09-15 2008-03-20 Schering Corporation Azetidine and azetidone derivatives useful in treating pain and disorders of lipid metabolism
WO2008033431A1 (en) * 2006-09-15 2008-03-20 Schering Corporation Spirocyclic azetidinone derivatives for the treatment of disorders of lipid metabolism, pain, diabetes and other disorders
MX2009002918A (es) * 2006-09-15 2009-03-31 Schering Corp Derivados azetidinona y sus metodos de uso.
CA2663502A1 (en) * 2006-09-15 2008-03-20 Schering Corporation Azetidinone derivatives and methods of use thereof
WO2008033456A1 (en) * 2006-09-15 2008-03-20 Schering Corporation Spiro-condensed azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabilism
EP2133347A4 (en) 2007-03-06 2010-03-17 Teijin Pharma Ltd 1-BIARYLAZETIDINONDERIVATE
WO2008130616A2 (en) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines as cb1 modulators
CN101796033A (zh) * 2007-06-28 2010-08-04 英特维特国际股份有限公司 作为cb1拮抗剂的取代的哌嗪
JP2010531874A (ja) * 2007-06-28 2010-09-30 インターベット インターナショナル ベー． フェー． Ｃｂ１アンタゴニストとしての置換ピペラジン
EP2403848A1 (en) 2009-03-06 2012-01-11 Lipideon Biotechnology AG Pharmaceutical hypocholesterolemic compositions
CN101993403B (zh) 2009-08-11 2012-07-11 浙江海正药业股份有限公司 氮杂环丁酮类化合物及医药应用
HUE052300T2 (hu) 2012-05-01 2021-04-28 Althera Life Sciences Llc Orális tablettakészítmény, amely a rozuvastatin és az ezetimib rögzített kombinációjából áll, hiperlipidémia és kardiovaszkuláris betegségek kezelésére
CN116889627A (zh) 2019-03-20 2023-10-17 雷杰纳荣制药公司 用固醇调节元件结合转录因子1(srebf1)抑制剂治疗脂质水平升高
EP3942047A1 (en) 2019-03-20 2022-01-26 Regeneron Pharmaceuticals, Inc. Treatment of increased lipid levels with sterol regulatory element binding protein cleavage-activating protein (scap) inhibitors
WO2025049568A1 (en) 2023-08-29 2025-03-06 Regeneron Pharmaceuticals, Inc. Treatment of muscle disorder with folliculin interacting protein 1 (fnip1) inhibitors and/or folliculin (flcn) inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US4803266A (en) * 1986-10-17 1989-02-07 Taisho Pharmaceutical Co., Ltd. 3-Oxoalkylidene-2-azetidinone derivatives
GB8719695D0 (en) * 1987-08-20 1987-09-30 Ici Plc Chemical process
NZ228600A (en) * 1988-04-11 1992-02-25 Merck & Co Inc 1-(benzylaminocarbonyl)-4-phenoxy-azetidin-2-one derivatives
US4983597A (en) * 1989-08-31 1991-01-08 Merck & Co., Inc. Beta-lactams as anticholesterolemic agents
US5120729A (en) * 1990-06-20 1992-06-09 Merck & Co., Inc. Beta-lactams as antihypercholesterolemics
DE69222532T2 (de) * 1991-07-23 1998-02-26 Schering Corp Substituierte beta-lactam-verbindungen als hypocholesterolemische mittel und verfahren zu deren herstellung
LT3300B (en) * 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
US5412092A (en) * 1993-04-23 1995-05-02 Bristol-Myers Squibb Company N-substituted 2-azetidinones
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5627176A (en) * 1994-03-25 1997-05-06 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
WO1995035277A1 (en) * 1994-06-20 1995-12-28 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
CA2235943C (en) * 1995-10-31 2002-10-01 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents

Also Published As

Publication number Publication date
HUT77088A (hu) 1998-03-02
EP0792264A1 (en) 1997-09-03
KR970707092A (ko) 1997-12-01
MX9703577A (es) 1997-08-30
FI972099A7 (fi) 1997-05-16
CN1174548A (zh) 1998-02-25
WO1996016037A1 (en) 1996-05-30
CN1083833C (zh) 2002-05-01
SK283860B6 (sk) 2004-03-02
RU2159243C2 (ru) 2000-11-20
NO308468B1 (no) 2000-09-18
NO972272L (no) 1997-05-16
PL320092A1 (en) 1997-09-15
CA2205202C (en) 2002-01-08
SK61697A3 (en) 1997-12-10
ATE213726T1 (de) 2002-03-15
FI972099A0 (fi) 1997-05-16
DK0792264T3 (da) 2002-04-22
BR9509669A (pt) 1997-10-28
ES2169162T3 (es) 2002-07-01
NZ296720A (en) 1999-03-29
HU227672B1 (en) 2011-11-28
US5633246A (en) 1997-05-27
CZ148697A3 (en) 1997-11-12
PT792264E (pt) 2002-07-31
AU4140196A (en) 1996-06-17
UA54381C2 (uk) 2003-03-17
AU698750B2 (en) 1998-11-05
KR100235806B1 (ko) 2000-02-01
FI116220B (fi) 2005-10-14
CA2205202A1 (en) 1996-05-30
JPH09512833A (ja) 1997-12-22
HK1002558A1 (en) 1998-09-04
DE69525643D1 (de) 2002-04-04
EP0792264B1 (en) 2002-02-27
NO972272D0 (no) 1997-05-16
PL184310B1 (pl) 2002-09-30
CZ289033B6 (cs) 2001-10-17
JP2908031B2 (ja) 1999-06-21
US5744467A (en) 1998-04-28

Similar Documents

Publication Publication Date Title
DE69525643T2 (de) Sulfur-substituierte azetdinone als hypocholesterolmischmittel
DE69525479T2 (de) 4-[(heterocycloalkyl-oder heteroaromatische)-substituiertes phenyl]-2-azetidinone zur verwendung als hypolipidemische agentien.
DE69222532T2 (de) Substituierte beta-lactam-verbindungen als hypocholesterolemische mittel und verfahren zu deren herstellung
DE69511687T2 (de) Substituierte azetidinon-verbindungen als hypocholesterolemische mittel
US5624920A (en) Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
DE69426924T2 (de) Spirocycloalkyl-substituierte azetidinone als hypocholesterolemische mittel
DE69418613T2 (de) Hydroxy-substituierte azetidinonderivate als hypocholesterolemische mittel
EP1112251B1 (fr) Derives d'azetidine, leur preparation et les medicaments les contenant
DE3613573A1 (de) Cyclopentylether und ihre herstellung sowie pharmazeutische formulierung
AT395425B (de) Neue thiophen-2-carbonsaeurederivate und verfahren zu deren herstellung
JPS61210031A (ja) 抗けいれん剤および抗てんかん剤としての３‐アリルオキシアゼチジンカルボキサミド
HK1002558B (en) Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
JPH06500315A (ja) ベンズアミド誘導体
CA2207627C (en) 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents

Legal Events

Date Code Title Description
8364 No opposition during term of opposition